Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INCCPIX · Entity 6757 | Director | March 18, 2026 | March 20, 2026 |
| PINNACLE FINANCIAL PARTNERS INCPNFP · Entity 70624 | Director | March 01, 2024 | March 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CUMBERLAND PHARMACEUTICALS INC
Report date March 18, 2026 · Filed March 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,656 |
Reported balance
After 2026-03-18 transaction · row 1
1 source rowRow 1 · 2026-03-18 · Grant · Acquired 1,800 · Balance 63,656 |
PINNACLE FINANCIAL PARTNERS INC
Report date March 01, 2024 · Filed March 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| PNFP Common StockSEC Table I · non-derivative | Direct | 24,168 |
Ending reported balance
After 2024-03-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-03-01 · Tax withholding · Disposed 239 · Balance 23,179 F1: Represents shares withheld to cover taxes due upon the vesting of certain restricted share awards. Row 2 · 2024-03-01 · Grant · Acquired 989 · Balance 24,168 F2: Represents shares with restrictions that lapse on March 1, 2025 based on attendance at Pinnacle Board and Committee meetings to which the above-named director serves. |
| Depositary SharesSEC Table I · non-derivative | Direct | 4,000 |
Reported balance
Holding disclosure · report date 2024-03-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,000 F3: Each depositary share represents a 1/40th interest in a share of the Issuer's 6.75% Fixed-Rate Non-Cumulative Perpetual Preferred Stock, Series B, no par value per share. Depositary shares purchased in an underwritten public offering. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld to cover taxes due upon the vesting of certain restricted share awards.
F2: Represents shares with restrictions that lapse on March 1, 2025 based on attendance at Pinnacle Board and Committee meetings to which the above-named director serves.
F3: Each depositary share represents a 1/40th interest in a share of the Issuer's 6.75% Fixed-Rate Non-Cumulative Perpetual Preferred Stock, Series B, no par value per share. Depositary shares purchased in an underwritten public offering.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 18, 2026 Filed Mar 20, 2026 21:23 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 1,800 | $2.80 | $5,040.00 |
DisclosureSEC source: 0001632384-26-000002 · wk-form4_1774041820.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,656 Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 1,000 | $5.17 | $5,170.00 |
DisclosureSEC source: 0001628280-25-013541 · wk-form4_1742332404.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,856 F1 · shares: Restricted stock award will vest 100% on March 17, 2026. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 00:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 1,000 | $1.71 | $1,710.00 |
DisclosureSEC source: 0001214659-24-005222 · marketforms-65375.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,356 F1 · shares: Restricted stock award will vest 100% on March 25, 2025. Read SEC document |
| March 25, 2024 Filed Jan 30, 2025 21:39 UTC Amendment | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 2,500 | $1.71 | $4,275.00 |
DisclosureSEC source: 0001628280-25-003185 · wk-form4a_1738273177.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,856 F1 · shares: This amendment is being filed solely to correct an administrative error in reporting the number of Securities Acquired by Reporting Owner on the original Form 4 submitted on March 26, 2024, which were reported as 1,000 shares granted on March 25, 2024, but should have been reported as 2,500 shares. This reflects an increase of 1,500 shares. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 14:46 UTC | PINNACLE FINANCIAL PARTNERS INC PNFP · Entity 70624 | GrantPNFP Common Stock | 989 | $0.00 | $0.00 |
DisclosureSEC source: 0001115055-24-000054 · wk-form4_1709581599.xml · nonDerivative · entry 2 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,168 F2 · shares: Represents shares with restrictions that lapse on March 1, 2025 based on attendance at Pinnacle Board and Committee meetings to which the above-named director serves. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 14:46 UTC | PINNACLE FINANCIAL PARTNERS INC PNFP · Entity 70624 | Tax withholdingPNFP Common Stock | 239 | $82.72 | $19,770.08 |
DisclosureSEC source: 0001115055-24-000054 · wk-form4_1709581599.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,179 F1 · shares: Represents shares withheld to cover taxes due upon the vesting of certain restricted share awards. Read SEC document |
| March 24, 2023 Filed Mar 27, 2023 21:39 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 1,000 | $1.92 | $1,920.00 |
DisclosureSEC source: 0001209191-23-021278 · doc4.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,356 F1 · shares: Restricted stock award will vest 100% on March 24, 2024. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 15:10 UTC | PINNACLE FINANCIAL PARTNERS INC PNFP · Entity 70624 | GrantPNFP Common Stock | 1,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-004174 · doc1.xml · nonDerivative · entry 2 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,418 F2 · shares: Represents shares with restrictions that lapse on March 1, 2024 based on attendance at Pinnacle Board and Committee meetings to which the above-named director serves. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 15:10 UTC | PINNACLE FINANCIAL PARTNERS INC PNFP · Entity 70624 | Tax withholdingPNFP Common Stock | 174 | $74.09 | $12,891.66 |
DisclosureSEC source: 0001567619-23-004174 · doc1.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,334 F1 · shares: Represents shares withheld to cover taxes due upon the vesting of certain restricted share awards. Read SEC document |
| January 20, 2023 Filed Jan 23, 2023 13:20 UTC | PINNACLE FINANCIAL PARTNERS INC PNFP · Entity 70624 | PurchasePNFP Common Stock | 1,000 | $72.26 | $72,260.00 |
DisclosureSEC source: 0001567619-23-001121 · doc1.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,508 F1 · shares: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $72.25 to $72.26. The reporting person undertakes to provide Pinnacle Financial Partners, Inc., any security holder of Pinnacle Financial Partners, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 21, 2022 Filed Dec 23, 2022 22:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 180 | $2.22 | $399.60 |
DisclosureSEC source: 0001209191-22-062651 · doc4.xml · nonDerivative · entry 15 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,356 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| December 20, 2022 Filed Dec 23, 2022 22:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 200 | $2.31 | $462.00 |
DisclosureSEC source: 0001209191-22-062651 · doc4.xml · nonDerivative · entry 14 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,176 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| December 19, 2022 Filed Dec 23, 2022 22:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 250 | $2.21 | $552.50 |
DisclosureSEC source: 0001209191-22-062651 · doc4.xml · nonDerivative · entry 13 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,976 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| December 16, 2022 Filed Dec 23, 2022 22:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 100 | $2.22 | $222.00 |
DisclosureSEC source: 0001209191-22-062651 · doc4.xml · nonDerivative · entry 12 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,726 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| December 15, 2022 Filed Dec 23, 2022 22:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 60 | $2.24 | $134.40 |
DisclosureSEC source: 0001209191-22-062651 · doc4.xml · nonDerivative · entry 11 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,626 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| December 14, 2022 Filed Dec 23, 2022 22:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 120 | $2.21 | $265.20 |
DisclosureSEC source: 0001209191-22-062651 · doc4.xml · nonDerivative · entry 10 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,566 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| December 13, 2022 Filed Dec 23, 2022 22:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 120 | $2.18 | $261.60 |
DisclosureSEC source: 0001209191-22-062651 · doc4.xml · nonDerivative · entry 9 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,446 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| December 12, 2022 Filed Dec 23, 2022 22:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.14 | $139.10 |
DisclosureSEC source: 0001209191-22-062651 · doc4.xml · nonDerivative · entry 8 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,326 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| December 09, 2022 Filed Dec 23, 2022 22:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.15 | $139.75 |
DisclosureSEC source: 0001209191-22-062651 · doc4.xml · nonDerivative · entry 7 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,261 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| December 08, 2022 Filed Dec 23, 2022 22:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.19 | $142.35 |
DisclosureSEC source: 0001209191-22-062651 · doc4.xml · nonDerivative · entry 6 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,196 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| December 07, 2022 Filed Dec 23, 2022 22:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.18 | $141.70 |
DisclosureSEC source: 0001209191-22-062651 · doc4.xml · nonDerivative · entry 5 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,131 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| December 06, 2022 Filed Dec 23, 2022 22:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.19 | $142.35 |
DisclosureSEC source: 0001209191-22-062651 · doc4.xml · nonDerivative · entry 4 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,066 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| December 05, 2022 Filed Dec 23, 2022 22:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.19 | $142.35 |
DisclosureSEC source: 0001209191-22-062651 · doc4.xml · nonDerivative · entry 3 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,001 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| December 02, 2022 Filed Dec 23, 2022 22:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.31 | $150.15 |
DisclosureSEC source: 0001209191-22-062651 · doc4.xml · nonDerivative · entry 2 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,936 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| December 01, 2022 Filed Dec 23, 2022 22:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.33 | $151.45 |
DisclosureSEC source: 0001209191-22-062651 · doc4.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,871 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 30, 2022 Filed Dec 23, 2022 22:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.32 | $150.80 |
DisclosureSEC source: 0001209191-22-062643 · doc4.xml · nonDerivative · entry 21 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,806 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 29, 2022 Filed Dec 23, 2022 22:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.34 | $152.10 |
DisclosureSEC source: 0001209191-22-062643 · doc4.xml · nonDerivative · entry 20 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,741 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 28, 2022 Filed Dec 23, 2022 22:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.37 | $154.05 |
DisclosureSEC source: 0001209191-22-062643 · doc4.xml · nonDerivative · entry 19 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,676 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 25, 2022 Filed Dec 23, 2022 22:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.31 | $150.15 |
DisclosureSEC source: 0001209191-22-062643 · doc4.xml · nonDerivative · entry 18 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,611 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 23, 2022 Filed Dec 23, 2022 22:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.29 | $148.85 |
DisclosureSEC source: 0001209191-22-062643 · doc4.xml · nonDerivative · entry 17 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,546 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 22, 2022 Filed Dec 23, 2022 22:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.37 | $154.05 |
DisclosureSEC source: 0001209191-22-062643 · doc4.xml · nonDerivative · entry 16 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,481 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 21, 2022 Filed Dec 23, 2022 22:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.38 | $154.70 |
DisclosureSEC source: 0001209191-22-062643 · doc4.xml · nonDerivative · entry 15 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,416 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 18, 2022 Filed Dec 23, 2022 22:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.27 | $147.55 |
DisclosureSEC source: 0001209191-22-062643 · doc4.xml · nonDerivative · entry 14 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,351 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 17, 2022 Filed Dec 23, 2022 22:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.29 | $148.85 |
DisclosureSEC source: 0001209191-22-062643 · doc4.xml · nonDerivative · entry 13 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,286 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 16, 2022 Filed Dec 23, 2022 22:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.31 | $150.15 |
DisclosureSEC source: 0001209191-22-062643 · doc4.xml · nonDerivative · entry 12 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,221 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 15, 2022 Filed Dec 23, 2022 22:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.35 | $152.75 |
DisclosureSEC source: 0001209191-22-062643 · doc4.xml · nonDerivative · entry 11 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,156 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 14, 2022 Filed Dec 23, 2022 22:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.32 | $150.80 |
DisclosureSEC source: 0001209191-22-062643 · doc4.xml · nonDerivative · entry 10 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,091 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 11, 2022 Filed Dec 23, 2022 22:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.32 | $150.80 |
DisclosureSEC source: 0001209191-22-062643 · doc4.xml · nonDerivative · entry 9 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,026 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 10, 2022 Filed Dec 23, 2022 22:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.37 | $154.05 |
DisclosureSEC source: 0001209191-22-062643 · doc4.xml · nonDerivative · entry 8 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,961 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 09, 2022 Filed Dec 23, 2022 22:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.37 | $154.05 |
DisclosureSEC source: 0001209191-22-062643 · doc4.xml · nonDerivative · entry 7 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,896 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 08, 2022 Filed Dec 23, 2022 22:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.42 | $157.30 |
DisclosureSEC source: 0001209191-22-062643 · doc4.xml · nonDerivative · entry 6 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,831 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 07, 2022 Filed Dec 23, 2022 22:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.45 | $159.25 |
DisclosureSEC source: 0001209191-22-062643 · doc4.xml · nonDerivative · entry 5 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,766 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 04, 2022 Filed Dec 23, 2022 22:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.42 | $157.30 |
DisclosureSEC source: 0001209191-22-062643 · doc4.xml · nonDerivative · entry 4 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,701 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 03, 2022 Filed Dec 23, 2022 22:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.44 | $158.60 |
DisclosureSEC source: 0001209191-22-062643 · doc4.xml · nonDerivative · entry 3 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,636 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 02, 2022 Filed Dec 23, 2022 22:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.54 | $165.10 |
DisclosureSEC source: 0001209191-22-062643 · doc4.xml · nonDerivative · entry 2 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,571 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 01, 2022 Filed Dec 23, 2022 22:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.53 | $164.45 |
DisclosureSEC source: 0001209191-22-062643 · doc4.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,506 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 31, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.54 | $165.10 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 25 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,441 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 28, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.52 | $163.80 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 24 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,376 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 27, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.49 | $161.85 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 23 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,311 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 26, 2022 Filed Nov 18, 2022 22:17 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $2.42 | $157.30 |
DisclosureSEC source: 0001209191-22-057942 · doc4.xml · nonDerivative · entry 22 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,246 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.